Hydra Valve Achieves 95 Percent Success in High-Risk Aortic Stenosis, IHJ Study
A recent prospective study published in the Indian Heart Journal in March 2026 demonstrates that the active-release Hydra self-expanding heart valve achieved a 95.0% device success rate in high-risk severe aortic stenosis patients. The novel valve delivered dramatic hemodynamic restoration, significantly reducing mean pressure gradients from 53.1 ± 12.5 mmHg to 8.7 ± 3.3 mmHg (p < 0.001).
While transcatheter aortic valve replacement (TAVR) has established non-inferiority to surgical aortic valve replacement (SAVR), persistent clinical challenges such as conduction disturbances and paravalvular leakage (PVL) highlight the ongoing need for refined valve deployment platforms. Addressing this clinical gap, Dr. Nagendra Boopathy Senguttuvan from Sri Ramachandra Institute of Higher Education and Research, Chennai, India, and colleagues initiated the GENESIS-II study to evaluate the 6-month safety profile and performance of the Hydra self-expanding THV incorporating a novel active release mechanism in high-surgical-risk severe aortic stenosis patients.
Therefore, the prospective, single-arm study evaluated transfemoral valve implantation in 40 high-risk severe aortic stenosis patients across 19 Indian centers between November 2021 and November 2023. Excluding patients with bicuspid anatomy, severe mitral regurgitation, or ejection fraction under 20%, the trial evaluated 30-day device success and safety alongside 6-month clinical outcomes.
Key Clinical Findings of the Study Includes:
- High Procedural Success: GENESIS-II recorded a 95.0% device success rate, demonstrating enhanced procedural performance compared to the original trial's 92.5%.
- Hemodynamic Restoration: GENESIS-II demonstrated a marked reduction in mean aortic gradient from 53.1 ± 12.5 mmHg to 8.7 ± 3.3 mmHg alongside effective orifice area expansion from 0.6 ± 0.2 cm² to 1.9 ± 0.4 cm² (p < 0.001).
- Favorable Safety Profile: GENESIS-II documented low 6-month all-cause mortality (5.0%) and cardiovascular mortality (2.5%), with zero occurrences of stroke, myocardial infarction, or major vascular complications.
- Minimal Conduction Interference: GENESIS-II reported a 7.9% new permanent pacemaker implantation rate among naive patients, performing comparably to balloon-expandable valves and lower than typical self-expanding platforms.
- Functional Improvement: GENESIS-II observed functional class gains in 94.6% of participants, alongside a significant 6-minute walk distance increase from 217.0 ± 50.9 m to 280.1 ± 86.1 m (p < 0.001).
The results suggest that the Hydra self-expanding THV with its active release mechanism delivers high procedural success (95.0%) and sustained hemodynamic restoration through 6 months. Furthermore, the low rate of cardiovascular mortality (2.5%) and complete absence of moderate-to-severe PVL confirm its role as an effective therapeutic option for high-risk surgical candidates.
These findings indicate that incorporating active release technology and supra-annular architecture into self-expanding valve platforms may help interventionalists optimize deployment precision, minimize PVL, and reduce conduction system disruptions in high-risk patients undergoing valve replacement.
Although constrained by a non-randomized single-arm design, a modest sample size of 40 patients, and site-reported assessments, this study highlights the potential of the platform while underscoring the value of prospective randomized trials with extended follow-up to definitively establish long-term valve durability.
Reference
Sonawane A, Chandra P, Jose J, Bansal S, Gupta R, Sudhir K, Senguttuvan NB. Safety and performance of the Hydra self-expanding THV: 6 months outcomes from the GENESIS-II study. Indian Heart Journal. 2026;78(2):201–205.
